Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.

MLA

Johansson, Erin, et al. “Cost-Effectiveness Analysis of Baricitinib versus Dupilumab for Moderate to Severe Atopic Dermatitis: An Italian Healthcare System Perspective.” Journal of Medical Economics, vol. 26, no. 1, Jan. 2023, pp. 1155–66. EBSCOhost, https://doi.org/10.1080/13696998.2023.2255495.

APA

Johansson, E., Giovannitti, M., Mezzetti, M., Lu, N., & Sabatino, S. (2023). Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. Journal of Medical Economics, 26(1), 1155–1166. https://doi.org/10.1080/13696998.2023.2255495

Chicago

Johansson, Erin, Massimo Giovannitti, Maurizio Mezzetti, Na Lu, and Silvia Sabatino. 2023. “Cost-Effectiveness Analysis of Baricitinib versus Dupilumab for Moderate to Severe Atopic Dermatitis: An Italian Healthcare System Perspective.” Journal of Medical Economics 26 (1): 1155–66. doi:10.1080/13696998.2023.2255495.